Men Jingwen, Li Jing, Zhang Tianyan, Chen Yang, Xu Bin, Hou Huinan, Sun Lu, Yue Haoran, Duan Zhaoyue, Gui Ting, Gai Zhibo
Innovative Institute of Chinese Medicine and Pharmacy, Shandong University of Traditional Chinese Medicine, Jinan, 250355, China.
Department of Pathology, Changqing District People's Hospital of Jinan, 250300, China.
Curr Drug Metab. 2025 Jun 23. doi: 10.2174/0113892002371501250610074757.
The clearance of digoxin in obese patients with renal impairment is reduced, leading to elevated serum concentrations and increased risks of digoxin toxicity. However, the exact mechanism of such alterations in obese patients remains unclear. Previous studies have suggested that the organic anion transport-ing polypeptide 4c1 (Oatp4c1, Slco4c1) mediates the elimination of digoxin at the basal membrane of the proximal tubule (PT), indicating its potential role in the pharmacokinetic changes in obese patients. This study aims to investigate the effects of a high-fat diet on digoxin pharmacokinetics and transporter expression in mouse models and further analyze its significance by detecting the expression of transporters in human renal tissue samples.
First, a high-fat diet (HFD)-induced obese mouse model was established. Mice were intraperitoneally injected with digoxin, and 24-hour urine samples and blood samples at five time points were collected. Pharmacokinetic evaluation was performed using liquid chromatography-tandem mass spectrometry. Renal pathological changes and the expression of digoxin transporters (Oatp4c1 and P-glycoprotein (P-gp)) were assessed using histological staining, Western blots (WB), as well as quantitative polymerase chain reaction (qPCR). Human renal pathologic alterations and expression of transporter proteins showed consistency with the results of animal experiments. To explore the potential use of gadolinium-ethoxybenzyl-diethylenetri-amine-pentaacetic acid (Gd-EOB-DTPA) as a marker for Oatp4c1 function, drug interactions between digoxin and Gd-EOB-DTPA were assessed in mice.
HFD-induced obese mice showed significant increases in body weight, blood glucose, and triglyceride, along with elevated blood concentration of digoxin, increased areas under the curve, reduced renal clearance rate (CLr), and prolonged half-life (t1/2). Histological staining revealed proximal tubular epithelial cell detachment and slight fibrosis in the kidney of the HFD group, with decreased expression of villin, the protein marker for PT. Immunofluorescent staining and Western blots for digoxin transporters showed a significant reduction of Oatp4c1 and P-gp proteins, suggesting that the renal elimination of digoxin was affected solely by the reduced level of Oatp4c1 and P-gp proteins. Co-administration of digoxin and Gd-EOB-DTPA resulted in a reduced clearance of Gd-EOB-DTPA, suggesting that both share the same transporter. The blood concentration of Gd-EOB-DTPA was higher (77.5%) in the HFD group. Renal magnetic resonance imaging (MRI) intensity was lower in the HFD group after Gd-EOB-DATP administration compared to the Chow group.
Obesity-induced kidney damage results in decreased Oatp4c1 and P-gp expression and function in PT, resulting in a reduction of digoxin renal clearance. The inhibition of Gd-EOB-DTPA clearance by digoxin co-administration and the increased Gd-EOB-DTPA blood concentration in the HFD group both sug-gest its potential use in characterizing the Oatp4c1 function in vivo.
肾功能不全肥胖患者地高辛清除率降低,导致血清浓度升高及地高辛中毒风险增加。然而,肥胖患者出现此类改变的确切机制尚不清楚。既往研究表明,有机阴离子转运多肽4c1(Oatp4c1,Slco4c1)介导近端小管(PT)基底膜对地高辛的清除,提示其在肥胖患者药代动力学变化中可能发挥作用。本研究旨在探讨高脂饮食对小鼠模型地高辛药代动力学及转运体表达的影响,并通过检测人肾组织样本中转运体的表达进一步分析其意义。
首先,建立高脂饮食(HFD)诱导的肥胖小鼠模型。小鼠腹腔注射地高辛,收集5个时间点的24小时尿液样本和血液样本。采用液相色谱 - 串联质谱法进行药代动力学评估。使用组织学染色、蛋白质免疫印迹法(WB)以及定量聚合酶链反应(qPCR)评估肾脏病理变化及地高辛转运体(Oatp4c1和P - 糖蛋白(P - gp))的表达。人肾病理改变及转运体蛋白表达与动物实验结果一致。为探索钆 - 乙氧基苄基 - 二乙烯三胺五乙酸(Gd - EOB - DTPA)作为Oatp4c1功能标志物的潜在用途,评估了地高辛与Gd - EOB - DTPA在小鼠体内的药物相互作用。
HFD诱导的肥胖小鼠体重、血糖和甘油三酯显著增加,同时地高辛血药浓度升高、曲线下面积增加、肾脏清除率(CLr)降低以及半衰期(t1/2)延长。组织学染色显示HFD组小鼠肾脏近端小管上皮细胞脱落和轻度纤维化,PT蛋白标志物绒毛蛋白表达降低。地高辛转运体的免疫荧光染色和蛋白质免疫印迹法显示Oatp4c1和P - gp蛋白显著减少,提示地高辛的肾脏清除仅受Oatp4c1和P - gp蛋白水平降低的影响。地高辛与Gd - EOB - DTPA联合给药导致Gd - EOB - DTPA清除率降低,表明二者共用相同的转运体。HFD组Gd - EOB - DTPA血药浓度更高(77.5%)。与正常饮食组相比,Gd - EOB - DATP给药后HFD组肾脏磁共振成像(MRI)信号强度更低。
肥胖诱导的肾损伤导致PT中Oatp4c1和P - gp表达及功能降低,从而使地高辛肾脏清除率降低。地高辛联合给药对Gd - EOB - DTPA清除的抑制作用以及HFD组Gd - EOB - DTPA血药浓度升高均提示其在体内表征Oatp4c1功能方面的潜在用途。